{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:10:50Z","timestamp":1760004650882,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jpba.2023.115629","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T03:00:46Z","timestamp":1692414046000},"page":"115629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma"],"prefix":"10.1016","volume":"235","author":[{"given":"Kyana Y.","family":"Garza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aashish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115629_bib1","unstructured":"WHO. WHO. Global Hepatitis Report, 2017. Available: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 24 March 2019. World Health Organisation. 2017."},{"key":"10.1016\/j.jpba.2023.115629_bib2","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotypes","volume":"Vol. 13","author":"Zein","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"issue":"10","key":"10.1016\/j.jpba.2023.115629_bib3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciz022","article-title":"Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease","volume":"69","author":"Gane","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jpba.2023.115629_bib4","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v22.i34.7824","article-title":"Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes","volume":"Vol. 22","author":"Petruzziello","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jpba.2023.115629_bib5","doi-asserted-by":"crossref","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jpba.2023.115629_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.jpba.2023.115629_bib7","doi-asserted-by":"crossref","DOI":"10.7150\/ijms.43079","article-title":"Direct-acting antiviral in the treatment of chronic hepatitis c: Bonuses and challenges","volume":"Vol. 17","author":"Zeng","year":"2020","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.jpba.2023.115629_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1060028019877128","article-title":"Glecaprevir\/pibrentasvir: the first 8-week, pangenotypic HCV treatment regimen for patients 12 years of age and older","volume":"Vol. 54","author":"Huff","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.jpba.2023.115629_bib9","doi-asserted-by":"crossref","DOI":"10.1515\/jtim-2017-0007","article-title":"Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction","volume":"5","author":"Geddawy","year":"2017","journal-title":"J. Transl. Int Med"},{"key":"10.1016\/j.jpba.2023.115629_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.12.007","article-title":"Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: a systematic literature review and meta-analysis","volume":"18","author":"Zoratti","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.jpba.2023.115629_bib11","article-title":"Prospects for long-acting treatments for hepatitis C","volume":"75","author":"Thomas","year":"2022","journal-title":"Clin. Infect. Dis."},{"journal-title":"Drugs@FDA","article-title":"A. mavyret full prescribing information","year":"2017","key":"10.1016\/j.jpba.2023.115629_bib12"},{"issue":"4","key":"10.1016\/j.jpba.2023.115629_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035759","article-title":"New details of HCV NS3\/4A proteinase functionality revealed by a high-throughput cleavage assay","volume":"7","author":"Shiryaev","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jpba.2023.115629_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01620-17","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir","volume":"62","author":"Ng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.jpba.2023.115629_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.jpba.2023.115629_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02558-16","article-title":"In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir","volume":"61","author":"Ng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.jpba.2023.115629_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 INfection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"New Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jpba.2023.115629_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/apt.15218","article-title":"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study","volume":"49","author":"Atsukawa","year":"2019","journal-title":"Aliment Pharm. Ther."},{"issue":"1","key":"10.1016\/j.jpba.2023.115629_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cpdd.350","article-title":"Pharmacokinetics, safety, and tolerability following single and multiple doses of pibrentasvir in a first-in-human study","volume":"7","author":"Lin","year":"2018","journal-title":"Clin. Pharm. Drug Dev."},{"issue":"2","key":"10.1016\/j.jpba.2023.115629_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2016.10.007","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of ABT-493: a first-in-human study","volume":"106","author":"Lin","year":"2017","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jpba.2023.115629_bib21","article-title":"Development and validation of a novel bioanalytical method for the simultaneous determination of glecaprevir and pibrentasvir in human plasma using reversed-phase high-performance liquid chromatography","volume":"21","author":"Pavani","year":"2022","journal-title":"Egypt. Pharm. J."},{"issue":"2","key":"10.1016\/j.jpba.2023.115629_bib22","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-018-2576-4","article-title":"Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment","volume":"75","author":"Kosloski","year":"2019","journal-title":"Eur. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.jpba.2023.115629_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s13318-017-0428-8","article-title":"Pharmacokinetic interactions and safety of coadministration of glecaprevir and pibrentasvir in healthy volunteers","volume":"43","author":"Lin","year":"2018","journal-title":"Eur. J. Drug Metab. Pharm."},{"issue":"04","key":"10.1016\/j.jpba.2023.115629_bib24","first-page":"561","article-title":"Quantification of glecaprevir and pibrentasvir with deuterated internal standards in spiked human plasma samples by LC\u2013ESI-MS\/MS.","volume":"16","author":"Kumar","year":"2022","journal-title":"Asian J. Pharm."},{"journal-title":"Food Drug Adm.","article-title":"Bioanalytical method validation guidance for industry","year":"2018","key":"10.1016\/j.jpba.2023.115629_bib25"},{"issue":"13","key":"10.1016\/j.jpba.2023.115629_bib26","doi-asserted-by":"crossref","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.jpba.2023.115629_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.10.020","article-title":"Glecaprevir\/pibrentasvir for 8\u00a0weeks in treatment-na\u00efve patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial.","volume":"72","author":"Brown","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.jpba.2023.115629_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31841","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in children with chronic HCV: Part 2 of the DORA study","volume":"74","author":"Jonas","year":"2021","journal-title":"Hepatology"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523003989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523003989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:34:06Z","timestamp":1760002446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523003989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":28,"alternative-id":["S0731708523003989"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115629","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of the direct acting antivirals glecaprevir and pibrentasvir in plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115629"}}